Pregnancy Outcome After Exposure to Migalastat for Fabry Disease: A Clinical Report

Case Reports in Obstetrics and Gynecology
doi 10.1155/2019/1030259
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After One Year

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

Clinical Utility Gene Card For: Fabry Disease

European Journal of Human Genetics
Genetics
2011English

Exposure to Degludec During Pregnancy: A Case Report

Cureus
2019English

Hearing Loss in Fabry Disease: Data From the Fabry Outcome Survey

European Journal of Clinical Investigation
MedicineBiochemistryClinical Biochemistry
2006English

Clinical Heterogeneity in Fabry Disease

Nervno-Myshechnye Bolezni
Neurology
2015English

Safety of Switching to Migalastat From Enzyme Replacement Therapy in Fabry Disease: Experience From the Phase 3 ATTRACT Study

American Journal of Medical Genetics, Part A
Genetics
2019English

Metabolic Progression to Clinical Phenotype in Classic Fabry Disease

Italian Journal of Pediatrics
Child HealthPediatricsPerinatology
2017English

A Hemodialysis Patient With Bone Disease After Pregnancy: A Case Report

BMC Nephrology
Nephrology
2019English

Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter Prospective Controlled Study

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy